“Many feel powerless in the face of unscrupulous corporate conduct, but the courtroom is one of the key venues in which meaningful relief can be achieved by those willing to engage in the necessary battles.”
Tyler has over a decade of experience in complex litigation, having contributed to nearly every facet of the firm’s practice since joining in 2013. His work spans early-stage case investigation through trial and appeal, with a particular focus on antitrust litigation.
Tyler has played a key role in briefing dispositive and class certification motions, leading large-scale discovery efforts, taking and defending depositions, and negotiating class action settlements. He is skilled at navigating complex factual and regulatory landscapes and frequently collaborates with expert witnesses on issues central to the success of his cases. Tyler’s efforts have helped secure millions of dollars in recoveries for individuals and businesses harmed by corporate misconduct.
Among his representative matters, Tyler was instrumental in In re Ranbaxy Generic Drug Application Antitrust Litigation (D. Mass.), where he worked closely with plaintiffs’ economists and regulatory experts, conducted depositions, and helped secure certification of three classes of prescription drug purchasers. He led the firm’s day-to-day litigation efforts in In re Surescripts Antitrust Litigation (N.D. Ill.), directing discovery strategy and contributing to the successful opposition of motions to exclude plaintiffs’ expert testimony, and In re Xyrem Antitrust Litigation (N.D. Cal.), where he played a critical role in developing plaintiffs’ evidence relating to the economic issues of antitrust impact and market power. Tyler also helped in preparation for the trials in In re Nexium Antitrust Litigation (D. Mass.), the first ever pay-for-delay case to go to trial after the Supreme Court’s decision in FTC v. Actavis, and In re Opana Antitrust Litigation (N.D. Ill.).
Tyler’s academic background includes research on the intersection of patent and antitrust law in the pharmaceutical industry and the obstacles to certifying indirect purchaser class actions. His work has also explored issues of standing in state antitrust suits and the application of economic principles to conduct in the pharmaceutical industry.
